N-[(苯基甲氧基)羰基]-3-[[(苯基甲氧基)羰基]氨基]-L-丙氨酸 | 65621-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[(苯基甲氧基)羰基]-3-[[(苯基甲氧基)羰基]氨基]-L-丙氨酸
• 英文名称: (S)-N,N'-dicarbobenzyloxy-2,3-diaminopropanoic acid
• 英文别名: L-2.3-bis-benzyloxycarbonylamino-propionic acid；L-2.3-Bis-benzyloxycarbonylamino-propionsaeure；(2S)-2,3-bis{[(benzyloxy)carbonyl]amino}propanoic acid；2(S),3-bis-(benzyloxycarbonylamino)propionic acid；(S)-2,3-Bis(((benzyloxy)carbonyl)amino)propanoic acid；(2S)-2,3-bis(phenylmethoxycarbonylamino)propanoic acid
• CAS: 65621-26-3
• 化学式: C₁₉H₂₀N₂O₆
• 分子量: 372.378
• InChiKey: YTQKWTMXEWAKAJ-INIZCTEOSA-N

物化性质

• 沸点：
  627.4±55.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  N-[(苯基甲氧基)羰基]-3-[[(苯基甲氧基)羰基]氨基]-L-丙氨酸 在 氯化亚砜 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 (S)-methyl 3-(((benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)propanoate
  参考文献：
  名称：

  Gangopadhyay, A. K.; Mathur, K. B., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1982, vol. 21, # 5, p. 483 - 484

  摘要：

  DOI：
• 作为产物：
  描述：

  L-2,3-二氨基丙酸 、 氯甲酸苄酯 以52%的产率得到
  参考文献：
  名称：

  JONES, RAYMOND C. F.;WARD, GARY J., TETRAHEDRON LETT., 29,(1988) N 31, C. 3853-3856

  摘要：

  DOI：

文献信息

• Use of malonomicin and analogs in fungicidal applications
  申请人：Werk Lowell Todd

  公开号：US20070173539A1

  公开（公告）日：2007-07-26

  The present invention is related to the use of malonomicin compounds and derivatives in fungicidal applications and to new derivatives of malonomicin.

  本发明涉及马洛诺霉素化合物及其衍生物在杀真菌应用中的使用，以及马洛诺霉素的新衍生物。
• Diamino acid derivatives as antihypertensives
  申请人：Schering Corporation

  公开号：US05298492A1

  公开（公告）日：1994-03-29

  Novel diamino acid derivative dual inhibitors of neutral endopeptidase and angiotensin converting enzyme of the formula ##STR1## wherein: Z is amino, lower alkylamino, di-(lower alkyl)amino R.sup.9 C(O)NH-- or an optionally substituted guanidino group; R.sup.1 is hydrogen or R.sup.7 R.sup.8 N--; R.sup.2 is hydrogen, lower alkyl, cyclolower alkyl, aryllower alkyl or heteroaryllower alkyl; and R.sup.3 is hydrogen, lower alkyl or cyclolower alkyl; or R.sup.2 and R.sup.3, together with the carbon to which they are attached, comprise a 3-7 membered carboxyclic ring; R.sup.4 is hydrogen, lower alkyl, aryl lower alkyl or heteroaryllower alkyl; R.sup.5 and R.sup.6 are independently hydroxy, lower alkoxy, amino, aryllower alkoxy, lower alkylamino and di-(lower alkyl)amino; R.sup.7 is R.sup.9 C(O)-- or R.sup.10 SO.sub.2 --; and R.sup.8 is hydrogen, lower alkyl, aryllower alkyl or aryl; or R.sup.7 and R.sup.8, together with the nitrogen to which they are attached, comprise a 5-7 membered ring; R.sup.9 is lower alkyl, aryllower alkyl, aryl, heteroaryllower alkyl, heteroaryl, lower alkoxy, aryllower alkoxy, amino, alkylamino or dialkylamino; R.sup.10 is lower alkyl, aryl lower alkyl, aryl, heteroaryl lower alkyl, amino, lower alkylamino, di-(lower alkyl)amino or heteroaryl; n is 1, 2, 3, 4 or 5; and m is 1, 2, 3, 4 or 5; or a pharmaceutically acceptable addition salt thereof, useful in the treatment of cardiovascular disorders, are disclosed.

  新型二氨基酸衍生物双重抑制剂，可同时抑制中性内肽酶和血管紧张素转换酶的化学式为##STR1##其中：Z为氨基、较低的烷基氨基、二-(较低烷基)氨基R.sup.9 C(O)NH--或可选择取代的胍基团；R.sup.1为氢或R.sup.7 R.sup.8 N--；R.sup.2为氢、较低的烷基、环较低烷基、芳基较低烷基或杂芳基较低烷基；R.sup.3为氢、较低的烷基或环较低烷基；或R.sup.2和R.sup.3与它们连接的碳一起构成3-7成员的环；R.sup.4为氢、较低的烷基、芳基较低烷基或杂芳基较低烷基；R.sup.5和R.sup.6独立地为羟基、较低的烷氧基、氨基、芳基较低烷氧基、较低烷基氨基和二-(较低烷基)氨基；R.sup.7为R.sup.9 C(O)--或R.sup.10 SO.sub.2 --；R.sup.8为氢、较低的烷基、芳基较低烷基或芳基；或R.sup.7和R.sup.8与它们连接的氮一起构成5-7成员的环；R.sup.9为较低烷基、芳基较低烷基、芳基、杂芳基较低烷基、杂芳基、较低的烷氧基、芳基较低烷氧基、氨基、烷基氨基或二烷基氨基；R.sup.10为较低烷基、芳基较低烷基、芳基、杂芳基较低烷基、氨基、较低烷基氨基、二-(较低烷基)氨基或杂芳基；n为1、2、3、4或5；m为1、2、3、4或5；或其药学上可接受的加盐物，适用于治疗心血管疾病。
• Schneider, Biochemische Zeitschrift, 1937, vol. 291, p. 328,338
  作者：Schneider

  DOI：——

  日期：——
• Synthesis and Activity of Dipeptides, Linked to Targeting Ligands, as Specific NK Cell Enhancers
  作者：Shaun D. Abbott、Lyne Gagnon、Mouna Lagraoui、Salam Kadhim、Giorgio Attardo、Boulos Zacharie、Christopher L. Penney

  DOI：10.1021/jm970734v

  日期：1998.5.1

  Water soluble analogues of the lipophilic immunostimulant, octadecyl D-alanyl-L-glutamine, BCH-527, were synthesized and evaluated for the ability to stimulate natural killer (NK) cells. One of these compounds in which the octadecyl chain of BCH-527 was replaced with a shorter chain alcohol, 6-(D-alanyl-L-glutaminylamino)hexan-1-ol, 9, displayed an in vitro stimulation of NK cells comparable to that of interleukin 2 (IL 2). However, when the hydroxyl of 9 was linked to L-fucose to yield 1-beta-[6-(D-alanyl-L-glutaminylamino)hex-1-yl]-L-fucopyranose (BCH-2537 1), the observed stimulation of NK cells was greater than that observed with IL 2. Further evaluation of these compounds revealed that the improved in vitro activity of BCH-2537 was more pronounced in vivo. That is, while both compounds significantly increased splenic NK cells, only BCH-2537 significantly increased the activity of these cells in vivo. In terms of a structure-activity relationship, NK cell activity was sensitive to minor structural modifications. It was influenced by conservative substitutions within the dipeptide, the length of the hydrocarbon chain, and the functionality at the end of the chain. No other compound enhanced NK cell activity to the extent exhibited by BCH-2537, although a few were equipotent to 9.
• Lipopeptide antifungal agents: Amine conjugates of the semi-synthetic pneumocandins L-731,373 and L-733,560
  作者：Robert A. Zambias、Catherine James、George K. Abruzzo、Kenneth F. Bartizal、Richard Hajdu、Randy Thompson、Karl H. Nollstadt、Jean Marrinan、James M. Balkovec

  DOI：10.1016/s0960-894x(97)00359-4

  日期：1997.8

  Amine conjugates of the semi-synthetic 1,3-beta-(D)-glucan synthesis inhibitors L-731,373 (3) and L-733,560 (4) were prepared and evaluated for in vitro and in vivo antifungal activity. Tricationic analogs were more potent than the dicationic which were more potent than the monocationic. The L-ornithine conjugate of 4 possessed excellent pharmacokinetic parameters but lacked sufficient antifungal spectrum for development. (C) 1997 Elsevier Science Ltd.